GlassScriptPhysician profile
Kelsey J Master
NPI 1821641051
$3,570.88
in general payments reported to CMS, 2019-2025
33 companies · $438 in 2025
The $438 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,255 · 2022: $981 · 2023: $569 · 2024: $328 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,241 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,240.79 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $629.67 | 2021-2024 | |
| Hologic Sales and Service, LLC | $303.97 | 2023-2025 | Aptima, Acessa Provu System, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Novo Nordisk INC | $242.07 | 2021-2023 | Wegovy |
| Mayne Pharma Commercial LLC | $238.78 | 2021-2025 | |
| Astellas Pharma US INC | $219.00 | 2023-2024 | Veozah |
| Amneal Pharmaceuticals LLC | $168.75 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.68 | 2022-2023 | Trulance, Xifaxan |
| Amgen INC. | $154.01 | 2021-2022 | |
| Exeltis, USA INC. | $150.68 | 2021-2025 | Slynd |
| Therapeuticsmd, INC. | $142.07 | 2021-2022 | |
| Organon LLC | $141.03 | 2022-2025 | Nexplanon |
| Millicent US INC | $114.91 | 2021-2025 | Intrarosa, Femlyv |
| Bayer Healthcare Pharmaceuticals INC. | $110.45 | 2023-2024 | |
| Shield Therapeutics INC | $105.97 | 2022-2025 | Accrufer |
| Sumitomo Pharma America, INC. | $105.10 | 2023-2025 | Myfembree |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $66.77 | 2021 | |
| Eisai INC. | $63.73 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $63.21 | 2022 | |
| Davol INC. | $47.36 | 2022-2024 | Arista Ah Flexitip |
| Lilly USA, LLC | $45.00 | 2024-2025 | Zepbound, Mounjaro |
| Agile Therapeutics, INC. | $42.84 | 2021 | |
| Pfizer INC. | $39.17 | 2023-2024 | |
| Avion Pharmaceuticals | $33.66 | 2022 | |
| Scynexis, INC. | $23.35 | 2022 | |
| Biogen, INC. | $21.34 | 2025 | Zurzuvae |
| Lupin INC. | $20.04 | 2021 | |
| Myovant Sciences INC. | $18.67 | 2022 | |
| Alfasigma USA, INC. | $18.28 | 2021 | |
| Urovant Sciences INC | $18.26 | 2022 | |
| Medtronic, INC. | $17.65 | 2023 | Ligasure |
| Pacira Pharmaceuticals Incorporated | $16.81 | 2023 | Exparel |
| Upsher-Smith Laboratories LLC | $15.96 | 2022 | |
| Vistapharm, INC. | $15.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Master listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.